LAG3 and melanoma: Following the favorable evidence in melanoma, current ongoing clinical trials are investigating safety and efficacy of anti-LAG3 drugs in NSCLC (NCT04623775, NCT04205552, NCT04140500, NCT03219268, NCT03365791, NCAGN02385, NCT03849469, NCT02750514, NCT02465060, NCT03780725, NCT03516981, NCT02460224, NCT03250832, NCT01968109, NCT03005782, NCT02966548, and NCT03459222).